Status:
UNKNOWN
Patient-reported and Clinical Outcomes in Adults With Relapsed or Refractory Hodgkin's Lymphoma Receiving Brentuximab Vedotin
Lead Sponsor:
Multinational Center for Quality of Life Research, Russia
Conditions:
Relapsed or Refractory Hodgkin's Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
The goal of this is study is focusing on assessment of patient-reported outcomes in terms of quality of life (QoL) and symptom profile as well on evaluation of clinical efficacy and safety of BV in pa...
Detailed Description
Information on QoL in patients with refractory/relapsed HL treated with BV is quite limited till now. Moreover, PRO data in patients treated for refractory/relapsed HL with BV, including long-term eff...
Eligibility Criteria
Inclusion
- Adult patients with confirmed diagnosis of relapsed or refractory HL
- At least 18 years of age at time of BV treatment decision
- Patients with relapsed or refractory HL who are not candidates for ASCT with prescribed treatment with BV as ≥2nd line therapy, and patients with relapse after ASCT with prescribed treatment with BV
- Patients with given informed consent
- Patients who are capable to fill out questionnaires
- Patients with expected life duration of at least 6 months
Exclusion
- Patients enrolled in clinical trials
- Patients with contraindications to BV in accordance with instruction for use
Key Trial Info
Start Date :
April 2 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2020
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT03440788
Start Date
April 2 2018
End Date
May 1 2020
Last Update
October 28 2019
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine
Chelyabinsk, Russia
2
Republican Clinical Oncology Center of the Ministry of Health of the Republic of Tatarstan
Kazan', Russia
3
N.I. Pirogov National Medical Surgical Center
Moscow, Russia
4
Clinical Onclological Center
Omsk, Russia